Back to Journals » Clinical Ophthalmology » Volume 6

Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results

Authors Thapa R, Maharjan N, Paudyal G 

Received 4 February 2012

Accepted for publication 10 May 2012

Published 12 July 2012 Volume 2012:6 Pages 1057—1062


Review by Single anonymous peer review

Peer reviewer comments 4

Video abstract presented by Raba Thapa

Views: 1278

Raba Thapa,1 Nhukesh Maharjan,2 Govinda Paudyal1

1Vitreo-retinal Service, Tilganga Institute of Ophthalmology, 2Research Department, Tilganga Institute of Ophthalmology, Kathmandu, Nepal

Purpose: The purpose of this study was to evaluate the long-term safety, anatomical, and visual outcomes following intravitreal bevacizumab (Avastin; Genentech) on macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Methods: A prospective, interventional case series study was conducted among patients with ME due to BRVO, from June 2008 to October 2011. Intravitreal bevacizumab (1.25 mg/0.05 mL) was given at 4–6 weekly intervals until the ME subsided, and cases were followed up for a year. Complete ophthalmic evaluations and measurement of central retinal thickness (CRT) by optical coherence tomography were performed at baseline and follow-up visits.
Results: Sixty-three eyes of 63 patients were included in the study. The mean age was 58.22 years (standard deviation [SD], 12.3). The CRT at baseline was 515.3 ± 189.4 µm, and it significantly improved at each follow-up, with a CRT of 233.6 ± 101.5 µm at 12 months. The best-corrected visual acuity (BCVA) at baseline was 0.82 ± 0.54, and it significantly improved at each follow-up, with a BCVA of 0.40 ± 0.25 at 12 months (P < 0.001). The BCVA was better in 76% of the patients with a more than three-line increase in 55.5% of the eyes. The average number of intravitreal bevacizumab injections was 3.1 (range, 1–6 injections). Recurrent ME occurred in 30.2% of cases. There were no major ocular or systemic adverse events.
Conclusion: Intravitreal bevacizumab appears to be a safe and effective drug for reducing ME and improving visual acuity secondary to BRVO at 12-month follow-up at a tertiary referral eye hospital in Nepal.

Keywords: branch retinal vein occlusion, bevacizumab, macular edema

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.